YASUDA Shohei
No ORCID on file
· 20 papers in corpus
· active 1997-1998
Frequent coauthors
- AJITO Keiichi 20
- KURIHARA Kenichi 20
- MIYAJIMA KAORI 20
- OKONOGI Tsuneo 20
- SHINEI RIE 20
- TANABE Kiyoshi 20
- TATSUTA KUNIAKI 20
- TABATA Yuji 20
- YAMAMOTO Yasuo 20
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1998
Compounds represented by the following formula (I) and pharmaceutically acceptable salts thereof are disclosed. The compounds have progesterone receptor binding inhibitory activity and, hence, can be used as therapeutic and prophylactic age…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…
1997
Compounds represented by general formula (I) and pharmaceutically acceptable salts thereof, which have progesterone receptor binding inhibitory activities and so are used as remedies and preventives for diseases in which progesterone partic…